RBC Capital Reiterates a Buy Rating on Legend Biotech Corporation (LEGN)

Legend Biotech Corporation (NASDAQ:LEGN) is one of the best strong buy stocks to invest in according to Wall Street. In a report released on September 12, Leonid Timashev from RBC Capital reiterated a Buy rating on Legend Biotech Corporation (NASDAQ:LEGN) and set a price target of $77.00.

Legend Biotech Corporation (LEGN): Among Takeover Rumors Hedge Funds Are Buying

Legend Biotech Corporation (NASDAQ:LEGN) reported CARVYKTI net trade sales of around $439 million in fiscal Q2 2025, with CARVYKTI demonstrating “positive long-term outcomes in the CARTITUDE-1 study with one-third of patients remaining progression-free for ≥5 years.”

Management also reported cash and cash equivalents, and time deposits of $1.0 billion as of June 30.

Legend Biotech Corporation (NASDAQ:LEGN) is a clinical-stage company that develops, discovers, manufactures, and commercializes novel therapies for oncology and other indications. It develops advanced cell therapies across an elaborate range of technology platforms. The company operates in the US, China, and other geographical segments.

While we acknowledge the potential of LEGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LEGN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.